

---

# European Journal of Pharmaceutics and Biopharmaceutics

[www.elsevier.com/locate/ejpb](http://www.elsevier.com/locate/ejpb)

---

## Aims and Scope

The *European Journal of Pharmaceutics and Biopharmaceutics* provides a medium for publication of novel and innovative research from the areas of Pharmaceutical Technology, Pharmaceutical Biotechnology and Biopharmaceutics.

Topics covered include: • Drug and pro-drug design, drug stability and drug development • Development, formulation and manufacturing of pharmaceuticals and biopharmaceuticals • Physical pharmacy, drug delivery systems, controlled release systems and drug targeting • Biopharmaceutics • Pharmaceutical analysis and pharmaceutical packaging • Quality control, GMP and regulatory aspects • Medical devices.

The following types of papers are considered by the Editors: Research Papers, Review Articles and Notes.

## The Rules of 3

The Editors and Editorial board have developed the “**Rules of 3**”. Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work:

1. The paper must report on recent advances in pharmaceutical technology, biopharmaceutics and pharmaceutical biotechnology of major importance.
2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.
3. The study described in the manuscript must represent a novel approach.

The rules are also used as guidelines for the peer review of manuscripts and are detailed on the journal homepage [www.elsevier.com/locate/ejpb](http://www.elsevier.com/locate/ejpb)

### *Editor-in-Chief*

**Prof. Robert Gurny**, School of Pharmaceutical Sciences, University of Geneva, 30, quai E.-Ansermet, CH-1211 Geneva 4, Switzerland

### *Editors*

**Prof. Gerrit Borchard**, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland

**Prof. Achim Göpferich**, Institute of Pharmacy, Pharmaceutical Technology, University of Regensburg, Regensburg, Germany

**Prof. Geoffrey Lee**, Institute for Pharmaceutical Technology, University of Erlangen-Nürnberg, Erlangen, Germany

**Prof. Claus-Michael Lehr**, University of Saarland, Department of Biopharmaceutics and Pharmaceutical Technology, Saarbrücken, Germany

**Prof. Jean-Christophe Leroux**, Galénische Pharmazie ETH, Zurich, Switzerland

**Prof. Karsten Mäder**, Institute of Pharmacy, Pharmaceutical Technology, Martin Luther University, Halle/Saale, Germany

**Prof. James W. McGinity**, College of Pharmacy, Drug Dynamics Institute, The University of Texas at Austin, Austin, TX, USA

### *Associate Editor*

**Dr. Michael Möller**, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland

## Editorial Advisory Board

**E. Allémann**, University of Geneva, Switzerland

**J.M. Anderson**, Case Western Reserve University, Cleveland, OH, USA

**S. Benita**, Hebrew University of Jerusalem, Israel

**J.-P. Benoit**, University of Angers, France

**A. Bernkop-Schnürch**, University of Innsbruck, Austria

**M.J. Blanco-Prieto**, University of Navarra, Pamplona, Spain

**R. Bodmeier**, Freie University of Berlin, Germany

**J. Breitenbach**, Abbott GbH & Co. KG, Ludwigshafen, Germany

**P. Breton**, Wavre, Belgium

**H. Bunjes**, Technical University of Braunschweig, Germany

**U. Conte**, University of Pavia, Italy

**P. Couvreur**, University of Paris Sud, France

**R. Daniels**, University of Tübingen, Germany

**F. Delie-Salmon**, University of Geneva, Switzerland

**J.M. Devoisselle**, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier, France

**E. Doelker**, University of Geneva, Switzerland

**J. Dressman**, J.W. Goethe University, Frankfurt, Germany

**P. Esposito**, Esteve, Martorelles, Spain

**B. Gander**, ETH Zürich, Switzerland

**W.R. Gombotz**, Omeros Corp., Seattle, WA, USA

**M. Gonzalez**, P'Kinetics International, Pembroke Pines, FL, USA

**R.H. Guy**, University of Bath, UK

**J. Hadgraft**, University of London, UK

**J.A. Hubbell**, EPFL, Lausanne, Switzerland

**H.E. Junginger**, Marburg, Germany

**Y.N. Kalia**, University of Geneva, Switzerland

**T. Kissel**, Philipps University, Marburg, Germany

**P. Kleinebudde**, H.-Heine University, Düsseldorf, Germany

**J. Knäblein**, Schering AG, Berlin, Germany

**J. Kopecek**, University of Utah, Salt Lake City, UT, USA

**J. Kreuter**, J.W. Goethe University, Frankfurt, Germany

**V.H.L. Lee**, The Chinese University of Hong Kong, Shatin, Hong Kong

**H. Lindner**, Bayer Schering Pharma AG, Berlin, Germany

**H.L. Luessen**, Tytonis BV, Alkmaar, The Netherlands

**E. Mathiowitz**, Brown University, Providence, RI, USA

**F.W.H.M. Merkus**, Leiden/Amsterdam Center for Drug Research, The Netherlands

**R.H. Müller**, Freie University of Berlin, Germany

**C. Müller-Goymann**, University of Braunschweig, Germany

**T. Nagai**, The Nagai Foundation, Tokyo, Japan

**R.H.H. Neubert**, Martin Luther University, Halle, Germany

**A.F. Öner**, Hacettepe University, Ankara, Turkey

**G.M. Pauletti**, University of Cincinnati, OH, USA

**N.A. Peppas**, University of Texas, Austin, TX, USA

**V. Préat**, Université Catholique de Louvain, Belgium

**M.J. Rathbone**, Gold Coast campus, Queensland, Australia

**S. Rudaz**, University of Geneva, Switzerland

**C. Rudolph**, Ludwig Maximilians University, Munich, Germany

**L. Scapozza**, University of Geneva, Switzerland

**R. Schubert**, Albert Ludwigs University, Freiburg, Germany

**J. Siepmann**, University of Lille, France

**K.J. Tojo**, Kyushu Institute of Technology, Lizuka, Fukuoka, Japan

**V. Torchilin**, Northeastern University, Boston, MA, USA

**C. Valenta**, University of Vienna, Austria

**J.L. Veuthey**, University of Geneva, Switzerland

**W. Weitschies**, University of Greifswald, Germany

**C.G. Wilson**, University of Strathclyde, Glasgow, UK

**G. Winter**, Ludwig Maximilian University, Munich, Germany

**A. Zimmer**, University of Graz, Austria